Do analysts prefer CVAC or NAGE?

Niagen Bioscience has a consensus price target of $10.50, indicating a potential upside of 206.12%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Niagen Bioscience is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has stronger earnings and valuation, NAGE or BIOA?

Niagen Bioscience has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Niagen Bioscience $130.42M 2.09 $17.38M $0.21 16.33 BioAge Labs $10.32M 108.16 -$80.61M -$2.40 N/A

Niagen Bioscience (NAGE) Competitors

$3.43 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$3.42 -0.01 (-0.15%)

As of 07/2/2026 06:49 PM Eastern

Compare

NAGE vs. CVAC, BIOA, CRON, ORIC, and OLMA

Should you buy Niagen Bioscience stock or one of its competitors? MarketBeat compares Niagen Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Niagen Bioscience include CureVac (CVAC), BioAge Labs (BIOA), Cronos Group (CRON), Oric Pharmaceuticals (ORIC), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry.

How does Niagen Bioscience compare to CureVac?

CureVac (NASDAQ:CVAC) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

In the previous week, CureVac's average media sentiment score of 0.00 equaled Niagen Bioscience'saverage media sentiment score.

Company	Overall Sentiment
CureVac	Neutral
Niagen Bioscience	Neutral

17.3% of CureVac shares are owned by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are owned by institutional investors. 2.2% of CureVac shares are owned by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Niagen Bioscience has a consensus price target of $10.50, indicating a potential upside of 206.12%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Niagen Bioscience is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

CureVac has a net margin of 199.92% compared to Niagen Bioscience's net margin of 14.29%. Niagen Bioscience's return on equity of 22.68% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Niagen Bioscience	14.29%	22.68%	16.23%

CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market.

CureVac has higher earnings, but lower revenue than Niagen Bioscience. CureVac is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Niagen Bioscience	$130.42M	2.09	$17.38M	$0.21	16.33

Summary

Niagen Bioscience beats CureVac on 9 of the 14 factors compared between the two stocks.

How does Niagen Bioscience compare to BioAge Labs?

Niagen Bioscience (NASDAQ:NAGE) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

15.4% of Niagen Bioscience shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by insiders. Comparatively, 20.8% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Niagen Bioscience has a net margin of 14.29% compared to BioAge Labs' net margin of -871.75%. Niagen Bioscience's return on equity of 22.68% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	14.29%	22.68%	16.23%
BioAge Labs	-871.75%	-29.40%	-27.26%

Niagen Bioscience has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$130.42M	2.09	$17.38M	$0.21	16.33
BioAge Labs	$10.32M	108.16	-$80.61M	-$2.40	N/A

In the previous week, BioAge Labs had 1 more articles in the media than Niagen Bioscience. MarketBeat recorded 1 mentions for BioAge Labs and 0 mentions for Niagen Bioscience. BioAge Labs' average media sentiment score of 1.37 beat Niagen Bioscience's score of 0.00 indicating that BioAge Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Niagen Bioscience	Neutral
BioAge Labs	Positive

Niagen Bioscience has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Niagen Bioscience currently has a consensus target price of $10.50, indicating a potential upside of 206.12%. BioAge Labs has a consensus target price of $43.50, indicating a potential upside of 73.31%. Given Niagen Bioscience's higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Niagen Bioscience beats BioAge Labs on 10 of the 16 factors compared between the two stocks.

How does Niagen Bioscience compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Niagen Bioscience has lower revenue, but higher earnings than Cronos Group. Niagen Bioscience is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59M	7.28	-$9.45M	$0.01	286.00
Niagen Bioscience	$130.42M	2.09	$17.38M	$0.21	16.33

Niagen Bioscience has a net margin of 14.29% compared to Cronos Group's net margin of -1.14%. Niagen Bioscience's return on equity of 22.68% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.14%	-1.26%	-1.20%
Niagen Bioscience	14.29%	22.68%	16.23%

Cronos Group presently has a consensus price target of $2.30, suggesting a potential downside of 19.58%. Niagen Bioscience has a consensus price target of $10.50, suggesting a potential upside of 206.12%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

8.7% of Cronos Group shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 7.8% of Cronos Group shares are held by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Cronos Group had 3 more articles in the media than Niagen Bioscience. MarketBeat recorded 3 mentions for Cronos Group and 0 mentions for Niagen Bioscience. Cronos Group's average media sentiment score of 0.55 beat Niagen Bioscience's score of 0.00 indicating that Cronos Group is being referred to more favorably in the media.

Company	Overall Sentiment
Cronos Group	Positive
Niagen Bioscience	Neutral

Cronos Group has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market.

Summary

Niagen Bioscience beats Cronos Group on 10 of the 15 factors compared between the two stocks.

How does Niagen Bioscience compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Niagen Bioscience has a net margin of 14.29% compared to Oric Pharmaceuticals' net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Niagen Bioscience	14.29%	22.68%	16.23%

Oric Pharmaceuticals presently has a consensus price target of $18.92, indicating a potential upside of 62.51%. Niagen Bioscience has a consensus price target of $10.50, indicating a potential upside of 206.12%. Given Niagen Bioscience's higher possible upside, analysts clearly believe Niagen Bioscience is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Niagen Bioscience. MarketBeat recorded 1 mentions for Oric Pharmaceuticals and 0 mentions for Niagen Bioscience. Oric Pharmaceuticals' average media sentiment score of 0.00 equaled Niagen Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Oric Pharmaceuticals	Neutral
Niagen Bioscience	Neutral

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Niagen Bioscience has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Niagen Bioscience	$130.42M	2.09	$17.38M	$0.21	16.33

Oric Pharmaceuticals has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

Summary

Niagen Bioscience beats Oric Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Niagen Bioscience compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

Niagen Bioscience has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Niagen Bioscience	$130.42M	2.09	$17.38M	$0.21	16.33

Niagen Bioscience has a net margin of 14.29% compared to Olema Pharmaceuticals' net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Niagen Bioscience	14.29%	22.68%	16.23%

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than Niagen Bioscience. MarketBeat recorded 1 mentions for Olema Pharmaceuticals and 0 mentions for Niagen Bioscience. Olema Pharmaceuticals' average media sentiment score of 0.84 beat Niagen Bioscience's score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Olema Pharmaceuticals	Positive
Niagen Bioscience	Neutral

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Olema Pharmaceuticals has a beta of 2, indicating that its share price is 100% more volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

Olema Pharmaceuticals presently has a consensus target price of $44.10, indicating a potential upside of 248.89%. Niagen Bioscience has a consensus target price of $10.50, indicating a potential upside of 206.12%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Niagen Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Niagen Bioscience beats Olema Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Niagen Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAGE vs. The Competition

Export

Metric	Niagen Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$273.18M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	16.33	21.61	28.02	24.70
Price / Sales	2.09	340.19	540.37	99.49
Price / Cash	16.91	147.12	49.26	57.09
Price / Book	3.57	8.66	10.96	6.46
Net Income	$17.38M	$23.81M	$3.57B	$337.01M
7 Day Performance	0.29%	3.39%	2.12%	1.69%
1 Month Performance	-0.58%	10.81%	5.25%	3.81%
1 Year Performance	-73.01%	62.61%	33.29%	23.90%

Niagen Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAGE Niagen Bioscience	3.7872 of 5 stars	$3.43 flat	$10.50 +206.1%	-73.0%	$273.18M	$130.42M	16.33	120	Analyst Forecast Gap Down
CVAC CureVac	N/A	$4.66 flat	$5.50 +18.0%	N/A	$1.05B	$70.74M	6.47	880
BIOA BioAge Labs	2.8823 of 5 stars	$23.36 +2.3%	$43.50 +86.2%	+486.4%	$1.03B	$8.99M	N/A	N/A
CRON Cronos Group	1.2481 of 5 stars	$2.71 -0.2%	$2.30 -15.0%	+40.2%	$1.01B	$146.59M	270.77	450
ORIC Oric Pharmaceuticals	1.9124 of 5 stars	$9.55 +1.3%	$18.92 +98.1%	+8.1%	$988.62M	N/A	N/A	80	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAGE) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Niagen Bioscience (NAGE) Competitors

NAGE vs. CVAC, BIOA, CRON, ORIC, and OLMA

How does Niagen Bioscience compare to CureVac?

Summary

How does Niagen Bioscience compare to BioAge Labs?

Summary

How does Niagen Bioscience compare to Cronos Group?

Summary

How does Niagen Bioscience compare to Oric Pharmaceuticals?

Summary

How does Niagen Bioscience compare to Olema Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAGE vs. The Competition

Niagen Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Niagen Bioscience (NAGE) Competitors

NAGE vs. CVAC, BIOA, CRON, ORIC, and OLMA

How does Niagen Bioscience compare to CureVac?

Does the media favor CVAC or NAGE?

Do institutionals and insiders have more ownership in CVAC or NAGE?

Do analysts prefer CVAC or NAGE?

Is CVAC or NAGE more profitable?

Which has more volatility and risk, CVAC or NAGE?

Which has stronger valuation and earnings, CVAC or NAGE?

Summary

How does Niagen Bioscience compare to BioAge Labs?

Do institutionals and insiders believe in NAGE or BIOA?

Is NAGE or BIOA more profitable?

Which has stronger earnings and valuation, NAGE or BIOA?

Does the media refer more to NAGE or BIOA?

Which has more risk & volatility, NAGE or BIOA?

Do analysts recommend NAGE or BIOA?

Summary

How does Niagen Bioscience compare to Cronos Group?

Which has stronger valuation & earnings, CRON or NAGE?

Is CRON or NAGE more profitable?

Do analysts rate CRON or NAGE?

Do institutionals & insiders hold more shares of CRON or NAGE?

Does the media refer more to CRON or NAGE?

Which has more risk & volatility, CRON or NAGE?

Summary

How does Niagen Bioscience compare to Oric Pharmaceuticals?

Is ORIC or NAGE more profitable?

Do analysts recommend ORIC or NAGE?

Does the media favor ORIC or NAGE?

Do institutionals and insiders believe in ORIC or NAGE?

Which has better earnings and valuation, ORIC or NAGE?

Which has more risk & volatility, ORIC or NAGE?

Summary

How does Niagen Bioscience compare to Olema Pharmaceuticals?

Which has better valuation & earnings, OLMA or NAGE?

Is OLMA or NAGE more profitable?

Does the media favor OLMA or NAGE?

Do institutionals & insiders believe in OLMA or NAGE?

Which has more volatility and risk, OLMA or NAGE?

Do analysts rate OLMA or NAGE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAGE vs. The Competition

Niagen Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools